These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38655752)

  • 1. GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease.
    Sun R; Srivastava A; Derebail VK; Han J; Molokie RE; Gordeuk V; Saraf SL
    Am J Hematol; 2024 Aug; 99(8):1610-1612. PubMed ID: 38655752
    [No Abstract]   [Full Text] [Related]  

  • 2. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
    JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diabetes therapy--novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors)].
    Gallwitz B
    MMW Fortschr Med; 2010 May; 152(20):43-4. PubMed ID: 20552881
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular effects of antidiabetic drugs.
    Sørensen AM; Christensen MB
    Drugs Today (Barc); 2018 Sep; 54(9):547-559. PubMed ID: 30303495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.
    Deol H; Lekkakou L; Viswanath AK; Pappachan JM
    Endocrine; 2017 Jan; 55(1):173-178. PubMed ID: 27696231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis.
    Lee YM; Lee SH; Kim TH; Park EJ; Park YA; Jang JS
    Cardiol J; 2022; 29(3):499-508. PubMed ID: 33140391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.
    Fu EL; Wexler DJ; Cromer SJ; Bykov K; Paik JM; Patorno E
    BMJ; 2024 Jun; 385():e078483. PubMed ID: 38925801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
    Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications.
    Pineda ED; Liao IC; Godley PJ; Michel JB; Rascati KL
    J Manag Care Spec Pharm; 2020 May; 26(5):610-618. PubMed ID: 32347181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.
    Foer D; Beeler PE; Cui J; Karlson EW; Bates DW; Cahill KN
    Am J Respir Crit Care Med; 2021 Apr; 203(7):831-840. PubMed ID: 33052715
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK; Ye C; Campbell S; Retnakaran R
    JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT?
    Bloomgarden ZT; Handelsman Y
    Endocr Pract; 2015 Dec; 21(12):1442-4. PubMed ID: 26484408
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
    Simms-Williams N; Treves N; Yin H; Lu S; Yu O; Pradhan R; Renoux C; Suissa S; Azoulay L
    BMJ; 2024 Apr; 385():e078242. PubMed ID: 38663919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin.
    Meade LT; Mannka ML
    Ann Pharmacother; 2019 Nov; 53(11):1111-1116. PubMed ID: 31215219
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
    Sharma A; Verma S
    Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.
    Pradhan R; Yin H; Yu O; Azoulay L
    Diabetes Care; 2022 Apr; 45(4):819-829. PubMed ID: 35104330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.
    Lajara R
    Postgrad Med; 2019 Nov; 131(8):555-565. PubMed ID: 31580737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.